c-Met Monoclonal Antibody (3D4) | Invitrogen 37-0100 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

c-Met Monoclonal Antibody (3D4)

catalog :

37-0100

quantity :

100 µg

price :

US 500

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

3D4

reactivity :

human, mouse

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section, immunohistochemistry - frozen section, western blot knockout validation

more info or order :

Invitrogen product webpage

citations: 33

Published Application/Species/Sample/Dilution	Reference
western blot knockout validation; mouse; fig s1 ELISA; mouse	Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson A, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 2015;522:349-53 pubmed publisher
western blot; mouse; loading ...	Duplaquet L, Leroy C, Vinchent A, Paget S, Lefebvre J, Vanden Abeele F, et al. Control of cell death/survival balance by the MET dependence receptor. elife. 2020;9: pubmed publisher
western blot; human; 1:1000; loading ...; fig 4a	Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F, et al. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. Br J Cancer. 2019;120:527-536 pubmed publisher
flow cytometry; human; tbl 2 immunocytochemistry; human	Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler J, et al. Development of a Novel c-MET-Based CTC Detection Platform. Mol Cancer Res. 2016;14:539-47 pubmed publisher
western blot; human; 1:1000; loading ...; fig st3	Nassour J, Martien S, Martin N, Deruy E, Tomellini E, Malaquin N, et al. Defective DNA single-strand break repair is responsible for senescence and neoplastic escape of epithelial cells. Nat Commun. 2016;7:10399 pubmed publisher
western blot; human; fig s1	Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, et al. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015;6:29209-23 pubmed publisher
immunohistochemistry - paraffin section; human; 1:200	Kim Y, Jin D, Lee B, Cho E, Han J, Shim Y, et al. RARÎ²2 hypermethylation is associated with poor recurrence-free survival in never-smokers with adenocarcinoma of the lung. Clin Epigenetics. 2015;7:32 pubmed publisher
western blot; human; fig 2	Mahadevan D, Theiss N, Morales C, Stejskal A, Cooke L, Zhu M, et al. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST). Oncotarget. 2015;6:1954-66 pubmed
immunocytochemistry; human; 1:100	Xie Y, Lu W, Liu S, Yang Q, Carver B, Li E, et al. Crosstalk between nuclear MET and SOX9/?-catenin correlates with castration-resistant prostate cancer. Mol Endocrinol. 2014;28:1629-39 pubmed publisher
western blot; human	Martin V, Corso S, Comoglio P, Giordano S. Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. Mol Oncol. 2014;8:1561-74 pubmed publisher
immunohistochemistry - frozen section; human; 1:50; fig 4 western blot; human; 1:250; fig 2	Lee S, Seol H, Lee H, Kang W, Kang B, Jin J, et al. Gene silencing of c-Met leads to brain metastasis inhibitory effects. Clin Exp Metastasis. 2013;30:845-54 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50	Jung Y, Joo K, Seong D, Choi Y, Kong D, Kim Y, et al. Identification of prognostic biomarkers for glioblastomas using protein expression profiling. Int J Oncol. 2012;40:1122-32 pubmed publisher
western blot; human; fig 3	Seiwert T, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69:3021-31 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50; loading ...; fig 2a	Kong D, Song S, Kim D, Joo K, Yoo J, Koh J, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115:140-8 pubmed publisher
	Phan Q, Solis N, Cravener M, Swidergall M, Lin J, Huang M, et al. Candida albicans stimulates formation of a multi-receptor complex that mediates epithelial cell invasion during oropharyngeal infection. PLoS Pathog. 2023;19:e1011579 pubmed publisher
	Mao X, Wang J, Luo F. α-Fetoprotein contributes to the malignant biological properties of AFP-producing gastric cancer. Open Life Sci. 2023;18:20220476 pubmed publisher
	Tauran Y, Lereau Bernier M, Segard B, Danoy M, Kimura K, Shinohara M, et al. A novel agonist for the HGF receptor MET promotes differentiation of human pluripotent stem cells into hepatocyte-like cells. Dev Growth Differ. 2022;64:527-536 pubmed publisher
	Hagege A, Saada Bouzid E, Ambrosetti D, Rastoin O, Boyer J, He X, et al. Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma. Cell Rep Med. 2022;3:100659 pubmed publisher
	De Nola G, Leclercq B, Mougel A, Taront S, Simonneau C, Forneris F, et al. Dimerization of kringle 1 domain from hepatocyte growth factor/scatter factor provides a potent MET receptor agonist. Life Sci Alliance. 2022;5: pubmed publisher
	Mao X, Wang J, Luo F. Alpha-fetoprotein can promote gastric cancer progression via upregulation of metastasis-associated colon cancer 1. Oncol Lett. 2022;23:84 pubmed publisher
	Wu X, Cheng Y, Matthen M, Yoon A, Schwartz G, Bala S, et al. Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion. J Exp Clin Cancer Res. 2021;40:70 pubmed publisher
	Diemer V, Ollivier N, Leclercq B, Drobecq H, Vicogne J, Agouridas V, et al. A cysteine selenosulfide redox switch for protein chemical synthesis. Nat Commun. 2020;11:2558 pubmed publisher
	Nisa L, Francica P, Giger R, Medo M, Elicin O, Friese Hamim M, et al. Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther. 2020;19:614-626 pubmed publisher
	Sa J, Kim S, Lee J, Cho H, Shin Y, Shin H, et al. Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma. Neuro Oncol. 2019;21:222-233 pubmed publisher
	Kwon M, Kim R, Song K, Jeon S, Jeong H, Kim J, et al. Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer. Oncotarget. 2017;8:92209-92226 pubmed publisher
	Kumai T, Matsuda Y, Ohkuri T, Oikawa K, Ishibashi K, Aoki N, et al. c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. Oncoimmunology. 2015;4:e976077 pubmed
	Schmitz K, Koeppen H, Binot E, Fassunke J, KÃ¼nstlinger H, Ihle M, et al. MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas. PLoS ONE. 2015;10:e0120079 pubmed publisher
	Malaquin N, Vercamer C, Bouali F, Martien S, Deruy E, Wernert N, et al. Senescent fibroblasts enhance early skin carcinogenic events via a paracrine MMP-PAR-1 axis. PLoS ONE. 2013;8:e63607 pubmed publisher
	Lennerz J, Kwak E, Ackerman A, Michael M, Fox S, Bergethon K, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803-10 pubmed publisher
	Dua R, Zhang J, Parry G, Penuel E. Detection of hepatocyte growth factor (HGF) ligand-c-MET receptor activation in formalin-fixed paraffin embedded specimens by a novel proximity assay. PLoS ONE. 2011;6:e15932 pubmed publisher
	Tuynman J, Lagarde S, ten Kate F, Richel D, van Lanschot J. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer. 2008;98:1102-8 pubmed publisher
	Tolgay Ocal I, Dolled Filhart M, D Aquila T, Camp R, Rimm D. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer. 2003;97:1841-8 pubmed
	Kang J, Dolled Filhart M, Ocal I, Singh B, Lin C, Dickson R, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 2003;63:1101-5 pubmed

product information

Product Type :

Antibody

Product Name :

c-Met Monoclonal Antibody (3D4)

Catalog # :

37-0100

Quantity :

100 µg

Price :

US 500

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Mouse

Reactivity :

Human

Applications :

ELISA: 0.1-1 µg/mL, Immunohistochemistry: 5-10 µg/mL, Immunoprecipitation: Assay-dependent, Western Blot: 1-3 µg/mL

Species :

Human

Clone :

3D4

Isotype :

IgG2a

Storage :

-20°C

Description :

MET (cMET) is a receptor-like tyrosine kinase whose dysregulation has been linked to many types of human malignancies. After activation of the ligand, MET interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, and STAT3. There interactions lead to the activation of signaling cascades including RAS-ERK, PI3, kinase-AKT, and PLCgamma-PKC. MET plays a role in embryonic development including gastrulation, development of muscles and neurons, angiogenesis, and kidney formation. It also plays a role in adults including wound healing, organ regeneration, and tissue remodeling. MET has been linked to cancers including gastric, renal, and breast; therefore, making it a target for cancer therapeutics and diagnostic testing.

Immunogen :

Synthetic peptide derived from cytoplasmic domain of human c-Met protein.

Format :

Liquid

Applications w/Dilutions :

ELISA: 0.1-1 µg/mL, Immunohistochemistry: 5-10 µg/mL, Immunoprecipitation: Assay-dependent, Western Blot: 1-3 µg/mL

Aliases :

AI838057; AUTS9; bHLHe59; CG1705; CG1705-PA; CG1705-PB; cmet; c-met; c-met proto-oncogene; c-Met receptor tyrosine kinase; c-Met/HGF receptor; D249; DFNB97; Dmel CG1705; Dmel_CG1705; DmMet; EC 2.7.10.1; Hepatocyte growth factor receptor; HGF; HGF receptor; HGF receptor c-Met; HGF/SF receptor; HGFR; HGF-SF receptor; juvenile hormone resistance; met; met proto-oncogene; met proto-oncogene (hepatocyte growth factor receptor); met proto-oncogene tyrosine kinase; MET proto-oncogene, receptor tyrosine kinase; Met/Met1; Met; protein tyrosin kinase; methoprene tolerant; Methoprene-tolerant; Methoprene-tolerant protein; Met-PA; Met-PB; Mett; oncogene MET; Par4; Proto-oncogene c-Met; RCCP2; resistance (1) juvenile H; resistance to juvenile hormone; Rst(1)JH; sc MET; scatter factor receptor; SF receptor; soluble c met; tyrosine-protein kinase Met

more info or order :

Invitrogen product webpage